NCT06049810CompletedPhase 3
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Retreatment Phase III Clinical Trial Evaluating the Efficacy and Safety of Subcutaneous Injection of IBI112 in the Treatment of Moderate to Severe Plaque Psoriasis.
Source: ClinicalTrials.gov · Last updated 17 Aug 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in the treatment of participants with moderate to severe psoriasis
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 566 (actual)
- First submitted
- 13 Sept 2023
- Start date
- 10 Oct 2023
- Primary completion date
- 29 Apr 2025
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Diseases
- Psoriasis
- NCT number
- NCT06049810
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 566
- From 10 Oct 2023 to the primary completion date, 29 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have ever received IBI112 or IL-23 inhibitor
- Is pregnant, nursing, or planning a pregnancy (both men and women) within 6 months following the last administration of the study drug
Other illness
- Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments
- History or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the participant
Who the study is looking for
- Have a diagnosis of plaque-type psoriasis for at least 6 months;
- Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND static Physician's Global Assessment (sPGA) score of 3 (moderate) or greater; Psoriasis covering at least 10% of body surface area;
- Must be a candidate for either systemic therapy or phototherapy for psoriasis.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Skin Disease Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.